BioCentury
ARTICLE | Emerging Company Profile

Biscayne: Antagonizing cancer

Biscayne's GHRH antagonist for cancer could be first in class

September 8, 2014 7:00 AM UTC

Biscayne Pharmaceuticals Inc. is developing peptide antagonists that target three different cancer growth pathways and could provide an alternative for prostate cancer patients who have become insensitive to hormone-based therapies. The company plans to enter the clinic by early 2016 with a potential first-in-class candidate targeting the GHRH receptor.

"Almost all of the therapies today for prostate cancer focus on hormone deprivation or the role of the androgen receptor and androgen deprivation. But patients eventually become insensitive to these therapies," said Samuel Reich, co-founder and CEO of Biscayne...